PLRX Quote, Financials, Valuation and Earnings

Aligos Therapeutics has a net margin of -- compared to Pliant Therapeutics's net margin of -1517.65%. Pliant Therapeutics's return on equity of -- beat Aligos Therapeutics's return on equity of -118.75%.

Pliant Therapeutics has a consensus price target of --, signalling upside risk potential of 197.86%. On the other hand Aligos Therapeutics has an analysts' consensus of $108.33 which suggests that it could grow by 162.67%. Given that Pliant Therapeutics has higher upside potential than Aligos Therapeutics, analysts believe Pliant Therapeutics is more attractive than Aligos Therapeutics.

Pliant Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Aligos Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Pliant Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Aligos Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pliant Therapeutics pays -- of its earnings as a dividend. Aligos Therapeutics pays out -- of its earnings as a dividend.

Pliant Therapeutics quarterly revenues are --, which are smaller than Aligos Therapeutics quarterly revenues of $1.3M. Pliant Therapeutics's net income of -$57.8M is lower than Aligos Therapeutics's net income of -$19.3M. Notably, Pliant Therapeutics's price-to-earnings ratio is -- while Aligos Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pliant Therapeutics is 161.82x versus 35.73x for Aligos Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

CEL-SCI has a net margin of -- compared to Pliant Therapeutics's net margin of --. Pliant Therapeutics's return on equity of -- beat CEL-SCI's return on equity of --.

Pliant Therapeutics has a consensus price target of --, signalling upside risk potential of 197.86%. On the other hand CEL-SCI has an analysts' consensus of -- which suggests that it could grow by 1004.76%. Given that CEL-SCI has higher upside potential than Pliant Therapeutics, analysts believe CEL-SCI is more attractive than Pliant Therapeutics.

Pliant Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CEL-SCI has a beta of 0.593, suggesting its less volatile than the S&P 500 by 40.711%.

Pliant Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pliant Therapeutics pays -- of its earnings as a dividend. CEL-SCI pays out -- of its earnings as a dividend.

Pliant Therapeutics quarterly revenues are --, which are smaller than CEL-SCI quarterly revenues of --. Pliant Therapeutics's net income of -$57.8M is lower than CEL-SCI's net income of -$6.9M. Notably, Pliant Therapeutics's price-to-earnings ratio is -- while CEL-SCI's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pliant Therapeutics is 161.82x versus -- for CEL-SCI. Usually stocks with elevated PS ratios are considered overvalued.

Haemonetics has a net margin of -- compared to Pliant Therapeutics's net margin of 9.79%. Pliant Therapeutics's return on equity of -- beat Haemonetics's return on equity of 13.51%.

Pliant Therapeutics has a consensus price target of --, signalling upside risk potential of 197.86%. On the other hand Haemonetics has an analysts' consensus of $110.80 which suggests that it could grow by 43.13%. Given that Pliant Therapeutics has higher upside potential than Haemonetics, analysts believe Pliant Therapeutics is more attractive than Haemonetics.

Pliant Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Haemonetics has a beta of 0.383, suggesting its less volatile than the S&P 500 by 61.749%.

Pliant Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Haemonetics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pliant Therapeutics pays -- of its earnings as a dividend. Haemonetics pays out -- of its earnings as a dividend.

Pliant Therapeutics quarterly revenues are --, which are smaller than Haemonetics quarterly revenues of $345.5M. Pliant Therapeutics's net income of -$57.8M is lower than Haemonetics's net income of $33.8M. Notably, Pliant Therapeutics's price-to-earnings ratio is -- while Haemonetics's PE ratio is 32.12x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pliant Therapeutics is 161.82x versus 2.92x for Haemonetics. Usually stocks with elevated PS ratios are considered overvalued.

IGC Pharma has a net margin of -- compared to Pliant Therapeutics's net margin of -416.75%. Pliant Therapeutics's return on equity of -- beat IGC Pharma's return on equity of -137.43%.

Pliant Therapeutics has a consensus price target of --, signalling upside risk potential of 197.86%. On the other hand IGC Pharma has an analysts' consensus of -- which suggests that it could grow by 914.89%. Given that IGC Pharma has higher upside potential than Pliant Therapeutics, analysts believe IGC Pharma is more attractive than Pliant Therapeutics.

Pliant Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison IGC Pharma has a beta of 1.288, suggesting its more volatile than the S&P 500 by 28.8%.

Pliant Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IGC Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pliant Therapeutics pays -- of its earnings as a dividend. IGC Pharma pays out -- of its earnings as a dividend.

Pliant Therapeutics quarterly revenues are --, which are smaller than IGC Pharma quarterly revenues of $412K. Pliant Therapeutics's net income of -$57.8M is lower than IGC Pharma's net income of -$1.7M. Notably, Pliant Therapeutics's price-to-earnings ratio is -- while IGC Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pliant Therapeutics is 161.82x versus 21.61x for IGC Pharma. Usually stocks with elevated PS ratios are considered overvalued.